Sorry for the Run-on sentences in advance. If you have any questions about my research or any data related to my blogs, just inquire about them via comment.
I am a 20 year old finance student studying the pharmaceutical industry and in particular the top performing industries of Biotech and life science research. I research companies that target untapped markets and follow capital expenditure trends of the industry to capitalize on surrounding opportunities. Companies working with government funded research institutions (NIH, Foundations, Universities) are my favorite long picks. I am long small caps with strong pipelines and balance sheets, and short most one trick unicorns that don't have value or technical support. I pick my trades on a company by company basis. I don't always require that a company is involved in a favorable industry that has unmet demand by big pharma, but that is where I believe discrepancies in valuations occur most often. Recently, I have moved with momentum and enjoy testing hype in valuations.
I use fundamental analysis, some historical pricing model techniques, and ultimately, macro themes to build and test my thesis's for industry analysis and trading. I always trade on technical analysis, but find value in fundamentals.
In 2016, my Biotech industry top picks are involved in the clinical development of therapies in ophthalmology (Dry eye, DME, AMD), rare diseases (MF, Lupus, DMD), lung disorders (COPD), cardiovascular diseases (PAH, DCM, CLI), and breakthrough cancer therapies (so basically anything Celgene, Roche, and Novartis miss).
Expecting a lot of crowding in Melanoma (ex. RXDX, ARRY) and cholesterol drugs (ex. $ESPR, $AEGR) in 2016 with multiple expected drug launches. Finally, I am excited for Biosimilars to make their debut in 2016. Many patent expirations in 2017 and before 2019 should open up some serious patent cases. I am still expecting a ton of BLAs to be filed in 2016 (ex. $PFNX, $EPRS, $MNTA, $SRNE).
Thanks for reading, tweet @Kuritzmike if you want to see what I'm trading on the day to day.
I joined Seeking Alpha in February 2014 as editor of the biotech vertical. In addition to onboarding new contributors, my job is to make sure Seeking Alpha provides high-quality and comprehensive coverage of the biotechnology and health care sectors. I am always looking for new ideas, so please reach out if you're interested.
Feel free to message me privately about my real-time subscription service.
For a better mobile experience on Seeking Alpha click the top right menu icon on most browsers and select "request desktop site".
I am a former financial communications programmer, turned full-time investor. I began investing in the mid-1990s, looking for a way to achieve early retirement. (A goal in which I have succeeded, if you don't consider full-time investing a job.) I took a scientific, experiment-based approach rather than a studious one. I feel that this approach, combined with my extensive programming work in financial markets and directly with traders has given me uncommon contrarian insight into what really drives market dynamics.
To that end, my articles will center around stocks and their derivatives because that's where I have the most experience (over 20 years). I may occasionally comment on currencies, where I believe I have a sound academic knowledge, but less trading experience.I will always refer to a company by name or some abbreviation thereof. By contrast, I will refer to the stock a company issues by its ticker symbol. I think it can be important to differentiate between the two.
It's been quite a journey the past four years as I've learned about stocks, technical analysis, swing trading, dividend growth investing, and now options.
For 17 years, I home educated our children and tutored, while my husband supported the family. Once I worked myself out of that job, I had to decide what I should be when I grow up. Without a useful degree, my income is minimal, but I really enjoy my part-time jobs. I have used my jobs as a learning tool more than an income tool and they have been very profitable. I focus the rest of my time making my husband's income the most useful it can be, and managing our home. I enjoy playing with bookkeeping, finance, investments, taxes, and strive to be the best steward of all the resources (time, energy, health, family, money, stuff) we have.
The only purpose of my investing was to be able to afford to retire at a normal, reasonable age and hopefully to live off the dividends from those investments without needing to spend down the principal. As health concerns are forcing us to consider earlier retirement, the portfolio income may be needed at anytime. This does not worry me, it just changes the trajectory of the portfolio. I am very thankful for the gentle start into investing and am excited by what might happen in the future.
I’m so glad this website was recommended to me and I genuinely appreciate the contributors and their comments here and the growth that has happened through participation on the forum.
In case you're wondering about 'inzkeeper', I formerly managed an inn and the email moniker has stuck with me over the years.
Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs and Seeking Alpha. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and attended post-baccalaureate and graduate courses in Business Administration, Quantitative Math, and Education at Florida Atlantic University, Georgia State University and University of North Carolina at Charlotte. In the past he has been an accountant, attorney, adjunct professor in Business Law, Accounting and Internal Auditing, financial advisor, supervisory principal, and compliance officer. He also passed the Georgia CPA Exam, the Certified Internal Auditor Exam, and the FINRA Series 7, 24 and 9/10 exams.He is presently also a contributor on MSN Top Stocks Blog, Motley Fool and is a member of the M100 on Marketocracy, an elete honor chosen by the editors of Marketocracy as being in the top 100 portfolio managers of over 100,000 portfoiios they review. He would enjoy hearing your comments at JimVanMeerten@gmail.com.
I am a fundamental investor focusing on undervalued stocks with asymmetric returns and a college student actively involved in the investment community at the University of California Berkeley. I avidly follow the stock market and am studying Economics with the goal of entering a finance related career when I graduate.
I am a value investor. I like to daytrade and ride stocks upward on good news and earnings beats. 2013 had a lot of those, but 2014 - not so much.
I am very new to investing and trading, and got into the market in late 2012 after pretend-investing for a few months, but I have had good luck so far.
I recently decided to try my hand at article writing, as I often leave rather detailed and lengthy comments on other articles. The amount of revisions required to get an article published was a bit discouraging, and did not allow me to mention opportunities in a timely fashion, so now I am back to just commenting.
In 2013, I was the windshield.
Started Trading at age 25 in late 2011, mostly invested in energy and tech stocks. I keep a close eye on coal in general. I'm interested in building a 2 part portfolio one part dividends and long term hold stocks mainly for retirement, the 2nd part is a growth portfolio which will hold my more risky picks in an effort to fund various fun things in life.
Update: 2013 was a decent year 2014 not so good as of 10/10/14.... Hoping the year turns around. Made some moves shrunk my portfolio a bit. Focus is still to retain 50-70% long term (1 year or more) dividend companies. Using the remaining funds for options trades and any swing trades that I think might work out.
World Traveler, Sports fanatic and amateur investor. BS Engineering, MSC Computer Science and MBA from Kellogg School of Management.
Currently COO/Partner at a Latin American E-Commerce site. I follow mostly Tech and Retail/E-Commerce companies.
A private investor with a Ph.D. in philosophy, a B.S. in music and about the same credentials in finance that a famous scarecrow once received from a wizard behind a curtain. I do however work mainly as an IT director in charge of financial systems - budget and contract stuff mainly.
I'm a retail investor that engages in both long-term and short-term trading. I look to build long-term positions in strong, dividend paying stocks. I also engage in short-term trading when I see stocks that I feel have been overly punished by the stock market. I used candlestick charting and technical analysis to identify entry and exit points for my trades.
Professionally, I am a CPA working for in the Oil Field Service industry (my day job). This keeps me from being the full time trader that I one day aspire to be.
President of MLP Protocol, investor, trader, and proponent of Master Limited Partnerships. Also on StockTwits and Twitter as @MLP_Protocol.
The primary driving force behind 99%+ of the activity on Seeking Alpha appears to be investors' confirmation bias. Do you want to be part of the 99% or are you trying to get to the 1%?
IF AN INVESTMENT GENERATES A K-1 INSTEAD OF A 1099-DIV I WON'T INVEST IN IT USING ANY TAX ADVANTAGED ACCOUNT. Here's why: http://www.wsj.com/articles/thousands-hit-with-surprise-tax-bill-on-income-in-iras-1447427436
Just a retired bureaucrat and pedant here who finds himself finally living his father's life. Saddled with the responsibility for managing his family's fortunes, like the Ancient Mariner, first reconciling myself and then finding beauty and joy in the mundane business of managing money. I like and collect old things...philosophies, stamps, coins, Wedgwood, what have you. My wife hates old things...except me, of course...or so she says. It's a life...and, for at least the time being, better than the alternative.
I am 71 years old, I retired at 62
I use the money to reinvest in stocks that have not reached the limit of 1000 shares The higher current dividends are in Utilities so I am primarily out there. But currently have 55 different stocks diversified across the board couple of Reits, 3 MLPs some consumer goods and some closed end funds. Also into a small experiment that pays high yield but the experiment involves less than 10k and and reinvests. Knowing that it is not the safest investments around it is cheap enough less than $20 a share pays monthly and yields 22% so far after 1 year no issues. Not recommended for the faint of heart or for those who have a fear of losing it. But I only live once (at least what I am aware of) so why not
current value of my IRA is 1.3 M. No debt own house and cars, live off SS and sometimes a monthly cash transfer of 4000 from accumulated dividends, Pay RMD tax out of now yearly withdrawal and use dividends to buy equities add on or new
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
My goal is to bring exposure to business development companies (BDCs) that finance small to medium sized businesses, typically overlooked by banks. BDCs are an instrument for investors to earn healthy dividends by avoiding double taxation at the corporate level and allowing income to flow directly to each shareholder. Please see website link below for more information.
The reports that I write are my personal research and opinions. They are not associated with any firm or organization, and are not intended to be taken as investment recommendations or advice. They combine my passions of economics, finance, writing and education, and are intended mostly as educational material. I attempt to write the articles in an easy to understand down to earth style in an effort to help others with their research. This is my effort to bring understandable and educational professional quality research to the public at large free of charge.
General Disclaimer for my Articles:
BS Business, Majored in Finance and Economics, Miami University
MA Economics w/ Managerial and International Emphasis, University of Oklahoma
Past: Economics and Finance Instructor at various Universities
Past: Mutual Fund Portfolio Manager of Family of Mutual Funds
Past: CIO of Mid-Sized Investment Management Firm
Professional: CFA Charterholder
Please note that the content of this site should not be construed as investment advice, nor do the opinions expressed necessarily reflect the views of CFA Institute.
I graduated from the University of Toronto with a BComm and am now working on developing a partnering business to help get the word out on disruptive investments. I want my research to provide timely and conclusive investment ideas that intend to deliver attractive yields to investors.
Keep updated with me on Twitter:
I enjoy following and capitalizing on investing opportunities primarily in the tech and healthcare industry. Most of my free time is spent conducting research on small-to-mid cap equities using a combination of fundamental data analysis and technical studies to come to conclusive results. I manage some money that I invest according to the above technique to ripen my exposure to the financial world.
Previously, I spent some time working for a major commercial construction company where I was responsible for running the back office, occasionally overlooking data and logistics. Most of my time was spent in a financial controller capacity.
I write because I believe in sharing my findings and opinions with those interested so they may come to their own conclusions and in turn spark an intelligent and beneficial discussion.
Interested in connecting? Shoot me a message
SPADE Indexes develops and manages sector, theme, and regional indexes used as the basis for investment products including exchange traded funds. Included among these is the SPADE Defense Index (NYSE: DXS), a benchmark for companies involved with defense, security, and space. The index serves as the underlying index for the Powershares Aerospace & Defense ETF (NYSE: PPA). The firm publishes a free newsletter "The SPADE Investor" which can be downloaded from the website. Other SPADE indexes are available for licensing.
SPADE Defense Index website: http://www.spadeindex.com
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship.
I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech.
I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.